MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Kymera Therapeutics Inc

Closed

SectorHealthcare

55.69 1.96

Overview

Share price change

24h

Current

Min

54.11

Max

55.97

Key metrics

By Trading Economics

Income

-11M

-77M

Sales

-11M

11M

EPS

-0.95

Profit margin

-667.602

Employees

218

EBITDA

-21M

-85M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+17.33% upside

Dividends

By Dow Jones

Next Earnings

31 Oct 2025

Market Stats

By TradingEconomics

Market Cap

1.5B

4.2B

Previous open

53.73

Previous close

55.69

News Sentiment

By Acuity

50%

50%

149 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Kymera Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Nov 2024, 03:00 UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

17.33% upside

12 Months Forecast

Average 64.13 USD  17.33%

High 88 USD

Low 53 USD

Based on 17 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

17

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

28.34 / 33.56Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

149 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat